08th week of 2011 patent applcation highlights part 50 |
Patent application number | Title | Published |
20110046134 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE - The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds. | 2011-02-24 |
20110046135 | NEW COMPOUNDS I - The present application relates to new compounds of formula (I), | 2011-02-24 |
20110046136 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH - The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene. | 2011-02-24 |
20110046137 | Pyrazole Derivatives as P2X7 Modulators - The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 2011-02-24 |
20110046138 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS - A series of novel compounds showing anticonvulsant activity is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures. | 2011-02-24 |
20110046139 | BENZOCYCLOHEPTANE AND BENZOXEPINE DERIVATIVES - The present invention relates to a compound of formula (I) | 2011-02-24 |
20110046140 | AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS - Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I): wherein R | 2011-02-24 |
20110046141 | USE OF PDE5 INHIBITORS FOR TREATING CIRCADIAN RHYTHM DISORDERS - A method of altering circadian rhythm in a mammal is provided. In certain embodiments, the method comprising: administering to the mammal a PDE5 inhibitor, e.g., sildenafil, vardenafil, tadalafil or zaprinast. The method may be employed to prevent a circadian rhythm disorders including, but not limited to transmeridian flight disorder (i.e., “jet-lag”), shiftwork-related disorder, seasonal affected disorder and insomnia by phase delay or phase advance. | 2011-02-24 |
20110046142 | ANTIBIOTIC COMPOUNDS - Methods for identifying prodrug antibiotic compounds and direct inhibitory antibiotic compounds utilizing various screens are provided. Also provided are methods for treating infections using these compounds. | 2011-02-24 |
20110046143 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. | 2011-02-24 |
20110046144 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS - Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X | 2011-02-24 |
20110046145 | Quinolizidinone M1 Receptor Positive Allosteric Modulators - The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 2011-02-24 |
20110046146 | Phosphodiesterase 4 inhibitors -
PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I:
| 2011-02-24 |
20110046147 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES - The invention relates to 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) inhibitors, the preparation thereof and the use thereof for the treatment and prophylaxis of hormone-related, especially estrogen-related or androgen-related, diseases. | 2011-02-24 |
20110046148 | Spirocyclic Heterocycles Medicaments Containing Said Compounds, Use Thereof And Method For Their Production - The present invention relates to spirocyclic heterocycles of general formula (I) | 2011-02-24 |
20110046149 | 2-AMINO-3-SULPHONYL-TETRAHYDRO-PYRAZOLO[1,5-A]PYRIDO-PYRIMIDINE ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND USE THEREOF - The invention relates to serotonin 5-HT | 2011-02-24 |
20110046150 | USE OF N--4-(3-PYRIDYL)-2-PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY HYPERTENSION - The present invention pertains to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I | 2011-02-24 |
20110046151 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR - The present invention is directed to piperazinyl derivatives useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor. | 2011-02-24 |
20110046152 | Amide Compounds, Preparation Methods and Uses Thereof - Amide compounds, preparation methods and uses thereof. The structure of the compounds is represented as the general formula (I), in which the definitions of substituents are illuminated as description. | 2011-02-24 |
20110046153 | Medicaments - A compound of formal (I) is described: wherein R | 2011-02-24 |
20110046154 | USE OF AMINOPEPTIDASE INHIBITORS OR AZAINDOLE COMPOUNDS FOR PREVENTING OR TREATING CANCEROUS METASTASES FROM EPITHELIAL ORIGIN - The invention relates to the use of a compound selected from an aminopeptidase-inhibiting compound and an azaindole compound for producing a drug for preventing or treating cancerous metastases in humans or animals. | 2011-02-24 |
20110046155 | HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 - The invention provides an acid addition salt of a compound of the formula (1) Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogues thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new medical uses of compounds of the formula (1) and its ethyl analogue. | 2011-02-24 |
20110046156 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS - Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity. | 2011-02-24 |
20110046157 | Substituted hydroxamic acids and uses thereof - This invention provides compounds of formula (I): | 2011-02-24 |
20110046158 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS - The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. | 2011-02-24 |
20110046159 | Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes - The present invention relates to arylpyrazinone derivatives of formula (I), wherein R1, R2, R3 and A are as defined in claim | 2011-02-24 |
20110046160 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. | 2011-02-24 |
20110046161 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 2011-02-24 |
20110046162 | FUSED CYANOPYRIDINES AND THE USE THEREOF - The present application relates to novel substituted fused cyanopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular disorders. | 2011-02-24 |
20110046163 | FURANOPYRIMIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE - Furanopyrimidine cannabinoid analog compounds of the formula I are disclosed. | 2011-02-24 |
20110046164 | Purine Derivatives for Treatment of Cystic Diseases - Provided herein are methods of treatment of a cystic disease by administering a compound of Formula I. In certain embodiments, the compound for use in the methods provided herein is roscovitine or an analog thereof. | 2011-02-24 |
20110046165 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS - Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein. | 2011-02-24 |
20110046166 | PURINE DERIVATIVES AS A3 ADENOSINE RECEPTOR-SELECTIVE AGONISTS - Disclosed are (N)-methanocarba adenine nucleosides, e.g., of formula (I) as highly potent A | 2011-02-24 |
20110046167 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE - The present invention relates to compounds of the general formula (I) which are inhibitors of 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds. | 2011-02-24 |
20110046168 | METHODS OF TREATING DISEASES USING QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - A compound of general formula I | 2011-02-24 |
20110046169 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF - The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. | 2011-02-24 |
20110046170 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES - The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. | 2011-02-24 |
20110046171 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS - This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description. | 2011-02-24 |
20110046172 | Medicinal Compositions - A composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone delivered to or reaching the plasma of a patient is in the range of from 7.5:1 to 12.4:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, which also serves to reduce the likelihood of abuse of the composition by drug addicts. Also provided are a method of treatment of pain and the use of naloxone and buprenorphine for the manufacture of a medicament. | 2011-02-24 |
20110046174 | KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME - The present invention concerns methods useful in treating a subject having diarrhea-predominant IBS (IBS-D) by administering N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable salt thereof to the subject. | 2011-02-24 |
20110046175 | BENZOFURAN CANNABINOID COMPOUNDS AND RELATED METHODS OF USE - Furanopyridine cannabinoid analog compounds of the formula I are disclosed. | 2011-02-24 |
20110046176 | FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE - Furanopyridine cannabinoid analog compounds of the formula I are disclosed. | 2011-02-24 |
20110046177 | THERAPEUTIC QUINOLINE AND NAPHTHALENE DERIVATIVES - Disclosed herein is a stable compound having a structure formula (I): therapeutic methods, compositions, and medicaments related thereto are also disclosed. | 2011-02-24 |
20110046178 | Thiazolylpiperidine Derivatives as Fungicides - Thiazolylpiperidine derivatives of the formula (I), | 2011-02-24 |
20110046179 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 2011-02-24 |
20110046181 | Short duration depot formulations - Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent. | 2011-02-24 |
20110046182 | EFFICIENT ASPIRIN PRODRUGS - Aspirin is one of the most widely used drugs in the treatment of inflammation, pain and fever. It has more recently found application in the prevention of heart attacks and stroke and is being studied as a cancer chemopreventative agent. Despite its value aspirin continues to be underutilized because it causes gastric bleeding. The technology under development potentially removes this problem. It is designed to reduce contact between the drug and the intestinal lining. An isosorbide aspirinate prodrug compound is thus provided. The compound has the general structure as shown in general formula (I) wherein Y is a C | 2011-02-24 |
20110046183 | CRYSTAL OF BENZIMIDAZOLE COMPOUND - Provided is a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole showing an X-ray powder diffraction pattern having characteristic peaks at interplanar spacings (d) of 10.06±0.2, 8.70±0.2, 6.57±0.2, 5.59±0.2 and 4.00±0.2 Angstroms. The present invention provides a stable antiulcer drug superior in the absorbability. | 2011-02-24 |
20110046184 | SOLID STATE FORMS OF RACEMIC ILAPRAZOLE - The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders. | 2011-02-24 |
20110046185 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof - The invention relates to compounds of formula (I) wherein the groups R and R′ A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs. | 2011-02-24 |
20110046186 | 1-Substituted Pyridyl-Pyrazolyl Amide Compounds and Uses Thereof - The present invention discoses a kind of 1-substituted pyridyl-pyrazolyl amide compounds and uses thereof. The compounds have structures as represented by the general formula I, wherein the definitions of each substituent showed in the specification. The compounds of formula I are novel and have excellent insecticidal and fungicidal activities and can be used for controlling insect pest and diseases. | 2011-02-24 |
20110046187 | ASSESSING CONGESTIVE HEART RISK IN PATIENTS TREATED OR POTENTIALLY TO BE TREATED WITH A PEROXISOME-PROLIFERATOR-ACTIVATOR-RECEPTOR-GAMMA AGONIST OR A THIAZOLIDINEDIONE - Methods are provided for assessing a patient being treated with a peroxisome-proliferator-activator-receptor-γ (PPAR-γ) agonist or a thiazolidinedione (TZD), or having a condition treatable with a peroxisome-proliferator-activator-receptor-γagonist or a thiazolidinedione. Methods include measuring a galectin-3 concentration or a change in a galectin-3 concentration in a body fluid of a patient being treated with a peroxisome-proliferator-activator-receptor-γ agonist or a thiazolidinedione. A comparison to galectin-3 levels or changes in comparable patients provides information indicative of congestive heart risk. | 2011-02-24 |
20110046188 | COMPOSITIONS COMPRISING NOVEL PPAR LIGANDS AND ANTI-HYPERLIPEMIC AGENTS - Methods are provided for treating or preventing conditions comprising hypertension and dyslipidemia using antihyperlipemic agents and compounds that antagonize the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs) and lower triglycerides or elevate blood HDL-cholesterol. Compositions are provided for treating or preventing conditions comprising hypertension and dyslipidemia, comprising antihyperlipemic agents which lower triglycerides and inhibit cholesterol synthesis such as statins, and compounds that antagonize or block the angiotensin II type 1 (AT1) receptor, activate PPARs and lower triglycerides or elevate blood HDL-cholesterol such as sartans. | 2011-02-24 |
20110046189 | HETEROARYL-SUBSTITUTED BICYCLIC SMAC MIMETICS AND THE USES THEREOF - The invention relates to heteroaryl-substituted bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis. | 2011-02-24 |
20110046190 | COMBINATIONS COMPRISING A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR - A combination therapy for treating patients suffering from pre-malignant colon lesions (e.g. polyps) and colon cancer, as well as other malignancies, is disclosed. The patient is treated concurrently with a cycloocygenase-2 inhibitor and at least one compound selected from the group consisting of a microtubule interfering agent, an epithelial growth factor receptor tyrosine protein kinase inhibitor and a vascular endothelial growth factor receptor tyrosine kinase inhibitor. | 2011-02-24 |
20110046191 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a β | 2011-02-24 |
20110046192 | THERAPEUTIC DRUG FOR HYPERTENSION OR PREHYPERTENSION - The present invention relates to a therapeutic drug or a preventive drug for hypertension or high-normal blood pressure, comprising (a) and (b) as active ingredients:
| 2011-02-24 |
20110046193 | DEFERACIROX DISPERSIBLE TABLETS - The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet. | 2011-02-24 |
20110046194 | 3-Triazolylphenyl-substituted sulphide derivatives as acaricides and insecticides - The present invention constitutes new 3-triazolylphenyl-substituted sulphide derivatives of the formula (I) | 2011-02-24 |
20110046195 | Non-Lactone Carbocyclic and Heterocyclic Antagonists and Agonists of Bacterial Quorum Sensing - Compounds which modulate quorum sensing in quorum sensing bacteria. Compounds of the invention inhibit quorum sensing and/or activate quorum sensing in various bacteria. Compounds that inhibit quorum sensing are particularly useful for inhibition of detrimental bacterial biofilm formation. Compounds that activate quorum sensing are particularly useful for promoting growth and biofilm formation of beneficial bacterial. | 2011-02-24 |
20110046196 | Insecticidal Fertilizer Mixtures - This invention relates to insecticidal fertilizer mixtures containing | 2011-02-24 |
20110046197 | 3-AMINOCARBAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND METHOD FOR THE PREPARATION THEREOF - A method for treating an inflammatory process selected from the group consisting of oedema, erythema, articular inflammation, rheumatoid arthritis, arthrosis, a colorectal tumor, a pulmonary carcinoma, an adenocarcinoma, and combinations thereof, in a person in need thereof, the method comprising administering to the person in need thereof, in an amount sufficient to treat the inflammatory process, a 3-aminocarbazole or a salt thereof. | 2011-02-24 |
20110046198 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac. | 2011-02-24 |
20110046199 | SMALL MOLECULE INHIBITORS OF HIV PROTEASES - Described herein are compounds, compositions, and methods for treating HIV and related diseases. | 2011-02-24 |
20110046200 | Use of antisense oligonucleotides to effect translation modulation - The present invention provides methods for modulating translation of an mRNA using antisense oligonucleotides. The methods result in the stimulation or inhibition of a change in reading frame or stop codon readthrough during translation. | 2011-02-24 |
20110046201 | METHODS AND COMPOSITIONS FOR SEAMLESS CLONING OF NUCLEIC ACID MOLECULES - The present invention is in the fields of biotechnology and molecular biology. More particularly, the present invention relates to cloning or subcloning one or more nucleic acid molecules comprising one or more type IIs restriction enzyme recognition sites. The present invention also embodies cloning such nucleic acid molecules using recombinational cloning methods such as those employing recombination sites and recombination proteins. The present invention also relates to nucleic acid molecules (including RNA and iRNA), as well as proteins, expressed from host cells produced using the methods of the present invention. | 2011-02-24 |
20110046202 | METHOD FOR TESTING A SUBJECT THOUGHT TO HAVE OR TO BE PREDISPOSED TO ASTHMA - The present invention concerns a method of testing a subject thought to have or be predisposed to having asthma, allergy, atopic disease or atopic sensitization, which comprises the step of analyzing a biological sample from said subject for (i) detecting the presence of a mutation associated with the over-expression of the ORMDL3 gene, and/or (ii) analyzing the expression of the ORMDL3 gene; a use, for treating and/or preventing asthma, allergy, atopic disease or atopic sensitization in a subject, of a compound which specifically inhibits the expression of the ORMDL3 gene; and an in vitro method of selecting a compound, which can be useful for treating asthma, allergy, atopic disease or atopic sensitization, characterized in that said method comprises the steps of: (a) obtaining a cell expressing the ORMDL3 gene, (b) contacting said cell with at least one compound, (c) comparing the expression of the ORMDL3 gene in the cell between the steps a) and b), and (d) selecting the compound, which induces a lower level of expression of the ORMDL3 gene in the cell contacted to that compound. | 2011-02-24 |
20110046203 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 2011-02-24 |
20110046204 | Human Zip1, Zinc and Citrate for Prostate Cancer Screening - The present invention provides methods of detecting prostate cancer employing biomarkers, including hZIP1, zinc and citrate. Also provided are antibodies to detect hZIP1 protein or peptides and an expression vector comprising a genetic sequence effective to increase uptake of zinc into a prostate cell upon expression thereof. Furthermore, methods of treating prostate cancer and of increasing uptake of zinc into a prostate cell are provided. | 2011-02-24 |
20110046205 | METHOD FOR DISSOLVING CHARGED NUCLEIC ACID IN AN ORGANIC LIQUID - The invention relates to a method for dissolving charged nucleic acids in an organic first liquid which is immiscible with water. The method comprises the following steps: a) providing a solution of the nucleic acids in an aqueous second liquid, b) precipitating the nucleic acids by adding a complexing agent to the second liquid, the complexing agent forming complexes with the nucleic acids that are insoluble in the second liquid, c) removing the complexes from the second liquid, d) dissolving the complexes in a third liquid which consists of an amphiphilic compound or which contains an amphiphilic compound, and e) mixing the third liquid with the first liquid. | 2011-02-24 |
20110046206 | DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION - The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. The motifs are defined by positioning of differentially modified nucleosides wherein at least the sugar moieties are different. More particularly, the present compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified to have an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif or a fully modified motif. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression. | 2011-02-24 |
20110046207 | C5a binding nucleic acids - The present invention is related to a nucleic acid, preferably binding to C5a, selected from the group comprising type A nucleic acids, type B nucleic acids, type C nucleic acids, type D nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 73 to 79. | 2011-02-24 |
20110046208 | NUCLEOLAR TARGETING OF THERAPEUTICS AGAINST HIV - The HIV regulatory proteins Tat and Rev accumulate in nucleoli of human cells. No functional role has been attributed to this localization. Recently it was demonstrated that expression of Rev induces nucleolar re-localization of some nuclear factors involved in Rev export. Thus, it is likely that the nucleolus plays a critical role in Rev-mediated export of singly spliced and unspliced HIV-1 RNAs. As a test for trafficking of HIV-1 RNAs into the nucleolus, a hammerhead ribozyme which specifically cleaves HIV-1 RNA was joined to the U16 snoRNA resulting in accumulation of the ribozyme within nucleoli of human cells. Stably transduced human T-cells expressing this nucleolar localized ribozyme dramatically suppressed HIV-1 replication, confirming a possible trafficking of the HIV RNA through the nucleoli of human cells. In addition, a TAR element which binds Tat was joined to the U16 snoRNA, also resulting in localization in the nucleoli and inhibiting HIV replication. | 2011-02-24 |
20110046209 | RNA-Induced Translational Silencing and Cellular Apoptosis - The invention is directed to RNA molecules that can be used to inhibit protein synthesis and to induce cells to undergo apoptosis. It also includes pharmaceutical compositions containing the RNAs that can be used in treating or preventing tumors; abnormal dermatological growths and viral infections. | 2011-02-24 |
20110046210 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS - Compounds of formula (IA) or (IB) are IKK inhibitors useful in the treatment of autoimmune and inflammatory diseases: wherein R | 2011-02-24 |
20110046211 | COMBINATION THERAPY OF HEDGEHOG INHIBITORS, RADIATION AND CHEMOTHERAPEUTIC AGENTS - The present invention relates to therapeutic combinations and methods of inhibiting the proliferation of cancerous cells, the abnormal growth of cells, and tumor cell growth using the combination of a hedgehog inhibitor with chemotherapy and/or radiation therapy. The present invention also relates to methods of enhancing the antiproliferative effect of chemotherapy and/or radiation therapy in a mammalian cancer patient undergoing either chemotherapy or radiation or a combination of radiation and chemotherapy by co-administering a therapeutically amount of a hedgehog inhibitor, concurrently or sequentially, with the chemotherapy and/or radiation therapy. | 2011-02-24 |
20110046212 | USE OF OLEUROPEIN AND DERIVATIVES IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS AND PATHOLOGIES ASSOCIATED WITH PROTEIN AGGREGATION PHENOMENA - This invention relates to the use of oleuropein, specifically oleuropein in non-glycated form, and its derivatives in the treatment of type 2 diabetes mellitus. Furthermore, this invention relates to the use of oleuropein, specifically oleuropein in non-glycated form, and its derivatives both from synthesis and from degradation, in the treatment of pathologies associated with protein aggregation phenomena. Specifically, this invention relates to the use of oleuropein to prepare a pharmaceutical formula for the prophylactic and therapeutic treatment of pathologies connected to or deriving from amyloid deposit. | 2011-02-24 |
20110046213 | Production of Delta 9 Tetrahydrocannabinol - Δ9 THC is obtained by extracting Δ9 THC and Δ9 THC carboxylic acid from plant material using a non-polar solvent and decarboxylating the Δ9 THC acid into Δ9 THC in the same solvent, without a solvent swap, in the presence of aqueous base. The Δ9 THC is then washed to remove inorganic impurities, still in the same original solvent. | 2011-02-24 |
20110046215 | ABNORMAL INTRAOCULAR PRESSURE TREATMENT - Methods and compositions for reducing intraocular pressure in a patient, particularly a human patient, are described. In particular, compositions are disclosed that contain an anthocyanoside or an extract comprising it, a proanthocyanidin or an extract comprising it and combinations thereof. The compositions are useful for lowering intraocular pressure. | 2011-02-24 |
20110046216 | STABLE COMPOSITIONS OF DEHYDROASCORBIC ACID - Stable liquid compositions containing the oxidized form of vitamin C known as dehydroascorbic acid are provided. The compositions comprise dehydroascorbic acid and a pharmacologically acceptable liquid organic polyol solvent for said dehydroascorbic acid, wherein said polyol solvent comprises about 50% or greater of the total weight of said composition. The compositions are useful as dietary supplements, skin-enhancers, concentrates, or research solutions. | 2011-02-24 |
20110046217 | USE OF 2,2'-CYCLOLIGNANS FOR INDUCING, RESTORING OR STIMULATING THE PIGMENTATION OF THE SKIN, HAIR OR HAIRS - The invention relates to the use of 2,2′-cyclolignanes in the cosmetic or pharmaceutical field for inducing, restoring or stimulating the pigmentation of the skin, hair or hairs. | 2011-02-24 |
20110046218 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE - The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet. | 2011-02-24 |
20110046219 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES - Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. | 2011-02-24 |
20110046220 | PARABEN COMPOUNDS - The invention relates to a | 2011-02-24 |
20110046221 | THERAPEUTIC INTERVENTION TO MIMIC THE EFFECT OF CALORIC RESTRICTION - Methods are provided for promoting longevity and decreasing the incidence of aging associated pathologies (e.g., cancer) by the administration of one or more of the following LFFA: linoleic, oleic and palmitic acid. Secondary LFFA derived from this set, as well as their CoA derivatives and synthetic analogs, are effective also in promoting longevity and delaying the onset of age associated disorders. In addition, interventions including LFFA and CoA LLFA formulations are described which protect the organism from acute physical stress, tissue damage and hypoxia (either due to trauma or secondary to surgical procedures. | 2011-02-24 |
20110046222 | FATTY ACID AMIDES AND USES THEREOF - Provided are fatty acid amides of amino acids, uses thereof and pharmaceutical compositions including them. | 2011-02-24 |
20110046223 | TREATMENT OF NEUROFIBROMATOSIS - Disclosed are methods of treating neurofibromatosis by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with colchicine. Also disclosed are pharmaceutical compositions comprising FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof; colchicine; and a pharmaceutically acceptable carrier. | 2011-02-24 |
20110046224 | METHODS TO ACCELERATE MUSCLE DEVELOPMENT, DECREASE FAT DEPOSITS, AND ENHANCE FEEDING EFFICIENCY IN PIGS - A natural method to promote or enhance food efficiency and muscle/fat ratio in animals is described, particularly for pigs, through the administration of an effective amount of pure ferulic acid, substantially pure ferulic acid or ferulic acid formulations. Prepared food and formulations for animals are also described, which can increase muscular development in pigs, decreasing fat deposits or promoting or increasing animal growth or enhancing food efficiency in an animal. Effective amounts of pure ferulic acid or substantially pure ferulic acid use in said food preparations and formulations are described. | 2011-02-24 |
20110046225 | Pharmaceutical formulation containing palmitoyl ethanolamide and stearoyl ethanolamide - The invention concerns new pharmaceutical formulations containing a blend of palmitoyl ethanolamide or PEA and stearoyl ethanolamide or SEA compounds as active principles. The formulation is suitable for oral, parenteral, topical, transdermic, rectal, sublingual, nasal, topical, transdermic, rectal, nasal or sublingual administration, whereby the dosage form of said formulations can be in patches, suppositories, ovules, pessaries, aerosol or spray, emulsions, suspensions, solutions. Said pharmaceutical formulations are useful for the treatment or prevention of skin pathologies, for the treatment or prevention of gynaecological pathologies, for the treatment of disorders or pathologies characterised by improper metabolism of fatty acids as well as for the treatment of disorders or pathologies characterised by inflammatory states | 2011-02-24 |
20110046227 | METHODS FOR CONCOMITANT ADMINISTRATION OF COLCHICINE AND A SECOND ACTIVE AGENT - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., atorvastatin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 2011-02-24 |
20110046228 | METHODS FOR ADMINISTRATION OF COLCHICINE WITH GRAPEFRUIT JUICE - Methods for safe administration of colchicine together with consumption of grapefruit juice are disclosed. | 2011-02-24 |
20110046229 | Controlled Release Drug Delivery Systems And Pharmaceutical Compositions Formed Therewith - The present invention relates to controlled release drug delivery systems. In one embodiment, the present invention relates to controlled release drug delivery systems comprising a combination of at least one polyacrylic acid and at least one enteric polymer. In another embodiment, the present invention relates to a controlled release pharmaceutical composition comprising the combination of at least one active pharmaceutical ingredient and a controlled release drug delivery system, where the controlled release drug delivery system comprises the combination of at least one polyacrylic acid and at least one enteric polymer. | 2011-02-24 |
20110046230 | Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof - Novel 3-[2-(dimethylamino)methyl-(cyclohex-1-yl)]-phenol maleate compounds corresponding to formula I | 2011-02-24 |
20110046231 | SOLID FORMS OF (.+-.)-O-DESMETHYLVENLAFAXINE SALTS - The present invention relates to solid forms of (±)-O-desmethylvenlafaxine salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides solid forms of acid addition salts of (±)-O-desmethylvenlafaxine wherein the acid counter ion is provided by an acid selected from the group consisting of oxalic acid, benzoic acid and lactic acid. | 2011-02-24 |
20110046232 | Orally Dissolving Formulations of Memantine - Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease. | 2011-02-24 |
20110046233 | GOSSYPOL DERIVATIVES, PRODUCTION METHOD THEREOF AND USES OF SAME - The present invention relates to compounds of general formula (1): | 2011-02-24 |
20110046234 | Retinaldehyde in the Treatment of Obesity, Diabetes and Other Conditions - The present invention is directed to methods of treating a patient for a disease or condition associated with adipogenesis or insulin resistance by administering a retinaldehyde compound to the patient or a compound that increases endogenous retinaldehyde levels by inhibiting the enzyme retinaldehyde dehydrogenase 1. | 2011-02-24 |
20110046235 | PRODUCTS COMPRISING, AND USES OF, DECARBOXYLATED PHENOLIC ACIDS DERIVED FROM CHLOROGENIC ACIDS OF COFFEE - The present invention relates to uses of decarboxylated phenolic acid derived from chlorogenic acid of coffee as well as products comprising decarboxylated phenolic acid derived from chlorogenic acid of coffee, especially a coffee extract, and methods of producing such products. Coffee comprises chlorogenic acids, according to the invention these chlorogenic acids can be transformed into decarboxylated phenolic acids. The resulting decarboxylated phenolic acids have antioxidant and/or anti-inflammatory properties and can be used as ingredients in food and beverage products and to treat certain health conditions. | 2011-02-24 |
20110046236 | ALCOHOLIC COMPOSITIONS HAVING A LOWERED RISK OF ACETALDEHYDEMIA - The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. | 2011-02-24 |
20110046237 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS - Disclosed herein are methods of treatment and prevention of diseases and disorders related to estrogen receptors comprising administering novel di-aromatic compounds to patients in need thereof. | 2011-02-24 |